Matrixyl Palmitoyl Pentapeptide-4 214047-00-4

99% up by HPLC

Product categories

New Products

Product Details

Product Information

Product name	Matrixyl / Palmitoyl Pentapeptide-4
CAS No.	214047-00-4
Synonyms	Matrixyl, Palmitoyl Pentapeptide, Palmitoyl Pentapeptide -3, Palmitoyl Pentapeptide-4
Sequence	Pal-Lys-Thr-Thr-Lys-Ser-OH
Molecular Formula	C39H75N7O10
Molecular Weight	802.05
Quality Standard	99% up by HPLC, Cosmetic grade
Appearance	White powder

COA of Palmitoyl Pentapeptide-4

Items	Specifications	Results
Appearance:	White or almost white fluffy powder	Conform
Solubility	Soluble in acetic acid, insoluble in water	Conform
Water content	≤ 8.0%	6.1%
Peptide purity(by HPLC)	≥ 98%	99.7%
Organic solvent Residue	Dichloromethane ≤ 0.060%	< 0.060%
Organic solvent Residue	N.N-Dimethvformamide ≤ 0.088%	< 0.088%
Conclusion	Meet the specification of enterprise standard

Usage

Similarly to copper peptides, Matrixyl stimulates the lower layers of the skin to heal themselves, thus accelerating the healing of wounds. Cells called fibroblasts are responsible for knitting together wounds of the skin. Palmitoyl Pentapeptide-4 stimulates the "matrix" layers in the skin -- primarily collagen and fibronectin. When stimulated, the skin produces more collagen. Loss of collagen is what leads to thinning skin and the wrinkling of newly inelastic skin. Matrixyl helps to counteract this natural part of the aging process.

Function of Palmitoyl Tetrapeptide-4

Palmitoyl Tetrapeptide-4 mimics the activity of DHEA, the youth hormone that functions to reverse IL-6 over-production, and therefore reduce the aging symptoms as well as the phenomenon of immunosenescence. Palmitoyl Tetrapeptide-4 can enhance the functions in a variety of skin care and color cosmetic formulation.

Hot Tags : palmitoyl pentapeptide-4 in skin care Palmitoyl Pentapeptide-4 Matrixyl powder Polypeptide powder Polypeptide manufacturer Polypeptide supplier

Send A Message

Related Products

Liraglutide 204656-20-2

Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage 2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: · Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. · Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). · Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. · Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.